The CCR9 Knockout THP-1 Polyclonal Cells represent a genetically disrupted human monocytic leukemia cell population in which the C-C chemokine receptor type 9 (CCR9) gene has been targeted by CRISPR/Cas9-mediated editing. This product is provided as a heterogeneous polyclonal pool, ensuring a loss-of-function model without selection of single-cell clones. The disruption strategy interferes with endogenous CCR9 expression, enabling researchers to interrogate CCR9-dependent signaling dynamics and cellular responses in a suspension cell background derived from peripheral blood of an infant with acute monocytic leukemia. This knockout model is ideally suited for in vitro functional assays investigating chemokine-mediated lymphocyte and monocyte trafficking, particularly to intestinal tissues.
THP-1 cells serve as a well-characterized host line for interrogating monocyte and macrophage biology. Originally isolated from the peripheral blood of a pediatric patient with acute monocytic leukemia, these suspension cells exhibit monocyte-like features and can be differentiated into macrophage-like phenotypes upon phorbol ester treatment. The THP-1 background provides a physiologically relevant platform to study chemokine signaling, adhesion cascades, and tumor-host interactions, especially in the context of inflammation-driven malignancies. The CD14-positive monocytic nature of this line makes it a robust model for examining innate immune cell migration and gut-homing mechanisms.
CCR9 functions as the cognate receptor for the thymus-expressed chemokine CCL25, mediating directional migration of lymphocytes and myeloid cells to the intestinal mucosa. Upon CCL25 binding, CCR9 couples to G??i proteins, initiating a signaling cascade that includes phospholipase C (PLC) activation, phosphatidylinositol 3-kinase (PI3K)?CAkt signaling, and mitogen-activated protein kinase (MAPK) pathway engagement. Downstream effectors include ERK1/2 phosphorylation, calcium mobilization, and actin polymerization, culminating in integrin ??4??7 activation and firm adhesion to mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Inflammatory cytokines such as TNF-?? and IL-1?? can upregulate CCR9 expression, amplifying gut-tropic responses. Additionally, CCR9 interacts with ??-arrestin2 and forms heterodimers with CXCR4, further diversifying its signaling outputs.
In the THP-1 monocytic context, ablation of CCR9 expression disrupts CCL25-induced chemotaxis, impeding downstream calcium flux, ERK1/2 phosphorylation, and integrin-mediated adhesion. This knockout model thereby allows precise dissection of the CCR9-CCL25 axis in monocyte trafficking, providing a tool to investigate how monocytic cells contribute to intestinal immune homeostasis and pathology. Because THP-1 cells express components of the selectin and integrin adhesion machineries, the CCR9 knockout facilitates studies on transendothelial migration and recruitment to inflamed gut endothelium, relevant to diseases such as inflammatory bowel disease and colorectal cancer metastasis.
Researchers can employ these polyclonal knockout cells in a variety of functional readouts, including transwell chemotaxis assays toward CCL25 gradients, calcium flux measurements using fluorescent indicators, phospho-ERK western blotting to assess MAPK activation, and flow cytometry to quantify integrin ??4??7 surface expression. The model is also suitable for adhesion assays on MAdCAM-1-coated surfaces and migration/invasion studies in 3D matrices. Key applications encompass intestinal immune cell trafficking research, drug target screening for gut-tropic inflammatory disorders, and elucidation of signaling networks governing colorectal cancer dissemination. Additional investigations may utilize RT-qPCR to confirm CCR9 transcript levels or co-culture systems with intestinal epithelial cells. For additional technical information or custom requests, please contact Ascent Research.
